Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 3 5Phase 2/3 3Phase 1 3Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 1

Interventions

nilotinib 4Cytarabine 3Filgrastim 2Cyclophosphamide 2Aprepitant 2Antilymphocyte Serum 2rasburicase 1liposomal amphotericin B 1fludarabine phosphate 1fludarabine 1bosutinib 1blinatumomab 1aldesleukin 1Water 1Voriconazole 1Urate Oxidase 1Tobacco Use Cessation Devices 1Thiotepa 1Rituximab 1Radiotherapy 1Psychiatric Rehabilitation 1Prilocaine 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Pentostatin 1Palonosetron 1Oxygen 1Interleukin-2 1Inotuzumab Ozogamicin 1Histamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia × Gemtuzumab × Clear all
NCT00304447 2009-07-29

Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 4 Completed
30 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡